Riskpilot← Back to searchSign inGet full accessBIOCAD Oy
OYActiveY-tunnus 2875102-5Tanssimäenkatu 7-B17Manufacture of pharmaceutical preparations · NACE 2120Est. 20171 employees
Revenue 2025
EUR 76K
0% vs 2024
EBITDA margin
-50.5%
0% vs 2024
Equity ratio
—
Financial strength
Net profit 2025
EUR -47K
0% vs 2024
| Revenue | EUR 76K | +0% |
| EBITDA | EUR -38K | +0% |
| Net profit | EUR -47K | +0% |
| Total assets | EUR 0 | -100% |
| Equity | EUR 600K | +1172% |
| Employees | 1 | — |
Legal name
BIOCAD Oy
Y-tunnus number
2875102-5
Legal form
Osakeyhtiö
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
8. joulukuuta 2017
Share capital
EUR 2 500
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-02-17
Financial year
January – December
Signatory rights
Selvitystilan aikana selvitysmies yksin
Company purpose
Yhtiön toimiala on lääkkeiden valmistus, toimittaminen, vienti ja jakelu sekä tutkimus- ja kehitystyö, prekliininen ja kliininen tutkimus, liiketoiminnan kehitys ja market access -toiminta.
Address
Tanssimäenkatu 7-B17
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 519 | 383 | 474 | 147 | 0 | 76 | 76 |
| Staff expenses | −192 | −190 | −124 | −116 | −111 | −55 | −55 |
| EBITDA | 88 | −45 | 116 | −228 | 2 | −38 | −38 |
| Depreciation & amort. | −28 | −53 | −53 | −275 | −8 | −8 | −8 |
| EBIT | 60 | −98 | 63 | −503 | −6 | −47 | −47 |
| Net financials | −25 | −25 | −1 | −0 | −0 | −0 | −0 |
| Profit before tax | 35 | −123 | 62 | −503 | −7 | −47 | −47 |
| Tax | 4 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | 31 | −123 | 62 | −503 | −7 | −47 | −47 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total assets | 659 | 589 | 607 | 94 | 74 | 74 | 0 |
| Equity | 18 | 495 | 557 | 54 | 47 | 47 | 600 |
| Long-term debt | 579 | — | — | — | 0 | 0 | 0 |
| Short-term debt | 63 | 94 | 50 | 40 | 27 | 27 | 0 |
| Total debt | 641 | 94 | 50 | 40 | 27 | 27 | 0 |
EBITDA margin
-50.5%
This company
15.8%
Market median
-420% vs market
20192025
Equity ratio
59982900.0%
This company
38.2%
Market median
+157023198% vs market
20192025
Return on equity
-7.8%
This company
18.4%
Market median
-142% vs market
20192025
Net profit margin
-61.6%
This company
8.1%
Market median
-860% vs market
20192025
Asset turnover
76236.00×
This company
1.12×
Market median
+6806686% vs market
20192025
Debt / equity
-1.00×
This company
0.62×
Market median
+261% vs market
20192025
- Annual report 2025Filed via PRH / YTJ · Period 2024-01-01 – 2025-02-17
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via PRH / YTJ · Period 2019-01-01 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
OP Chief Executive Officer | Chief Executive Officer | 2018 | — | — |
HJ Liquidator | Liquidator | 2024 | — | — |
KZ Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2018 | — | — | |
| Chairperson | 2018 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BIOCAD Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Oleg Pavlovskiy | Chief Executive Officer | 0 companies |
| Hannu Janne Kyllönen | Liquidator | 0 companies |
| Konstantin Zhukov | Chief Executive Officer | 0 companies |
| Roman A. Ivanov | Board of Directors | 0 companies |
| Svetlana Gorbunova | Board of Directors | 0 companies |
| Dmitry Morozov | Chairperson | 0 companies |